Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®);Utilidad de los registros electrónicos de medicamentos: Registro español de pacientes tratados con fingolimod (Gilenya ®)

Revista de Neurologia

Volumn 58, Issue 2, 2014, Pages 77-83

  Fernández, Óscar ^a   Rodríguez Antigüedad, Alfredo ^b   Oreja Guevara, Celia ^c   Garcia Garcia, Margarida ^d   Montalban, Xavier ^e  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d ADKNOMA Health Research SL   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Clinical epidemiological profile; Electronic case registry; Fingolimod; Multiple sclerosis; Treatment

Indexed keywords

FINGOLIMOD; GADOLINIUM; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC DRUG REGISTER; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REGISTER; RISK MANAGEMENT; ANALOGS AND DERIVATIVES; BRAIN; CLINICAL PRACTICE; CLINICAL TRIAL; CONFIDENTIALITY; DRUG EFFECTS; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; INFORMED CONSENT; PATHOLOGY; PATIENT DROPOUTS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; SPAIN; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

BRAIN; CONFIDENTIALITY; DRUG PRESCRIPTIONS; DRUG UTILIZATION; ELECTRONIC HEALTH RECORDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFORMED CONSENT; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PATIENT DROPOUTS; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING; PROPYLENE GLYCOLS; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; SPAIN; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84892704568     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5802.2013076     Document Type: Article

References (8)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
2. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
3. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002; 53: 285-302.
4. García-Merino JA, Sánchez AJ. Mecanismos básicos de acción del fingolimod en relación con la esclerosis múltiple. Rev Neurol 2012; 55: 31-7.
5. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
6. Cohen J, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
8. Jimeno FJ, Salgueiro E, González V, Manso G. Relevancia de las notificaciones de reacciones adversas a fármacos en atención primaria de Asturias. Semergen 2010; 36: 63-8.